Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4636887 | 0.89 | PTGDR2 (0.43) | POLBLMNAPTGS2PTGDR2CYP2C9 | |
| SCHEMBL4636153 | 0.86 | L3MBTL1 (0.41) | L3MBTL1SMN1; SMN2LMNAMAPTPTGS2 | |
| SCHEMBL27743110 | 0.85 | PTGDR2 (0.38) | PTGS2PTGDR2CYP2C9AKR1B1PTGS1 | |
| SCHEMBL4635997 | 0.84 | L3MBTL1 (0.40) | L3MBTL1SMN1; SMN2LMNAMAPTPTGS2 | |
| SCHEMBL2774837 | 0.84 | PTGDR2 (0.40) | POLBPTGS2PTGDR2CYP2C9PTGS1 | |
| SCHEMBL4636923 | 0.83 | L3MBTL1 (0.51) | L3MBTL1SMN1; SMN2LMNAMAPTPTGS2 | |
| SCHEMBL4635729 | 0.76 | SLC6A9 (0.34) | L3MBTL1POLBMAPTPTGS2PTGDR2 | |
| SCHEMBL27743111 | 0.76 | PTGDR2 (0.35) | PTGS2PTGDR2CYP2C9AKR1B1PTGS1 | |
| SCHEMBL4635633 | 0.76 | L3MBTL1 (0.40) | L3MBTL1SMN1; SMN2LMNAMAPTALDH1A1 | |
| SCHEMBL4635980 | 0.75 | L3MBTL1 (0.40) | L3MBTL1SMN1; SMN2LMNAMAPTPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306109-A1 | Indolizine Derivatives as Ligands of the Crth2 Receptor | ARGENTA DISCOVERY LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| EP-1931663-A1 | IMDOLIZINE DERIVATIVES AS LIGANDS OF THE CRTH2 RECEPTOR | Argenta Discovery Limited (GB) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007031747-A1 | IMDOLIZINE DERIVATIVES AS LIGANDS OF THE CRTH2 RECEPTOR | ARGENTA DISCOVERY LIMITED (GB) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306109-A1 | Indolizine Derivatives as Ligands of the Crth2 Receptor | HRH4, HRH2, HRH3 | L3MBTL1 3929/4885SMN1; SMN2 4618/4885POLB 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.